Illness trajectories are largely variable, and illness progression is not a general rule in BD. The number of manic episodes seems to be the clinical marker more robustly associated with neuroprogression in BD. However, the majority of the evidence came from cross-sectional studies that are prone to bias. Longitudinal studies may help to identify signatures of neuroprogression and integrate findings from the field of neuroimaging, neurocognition, and biomarkers.
Gerard Anmella, A. Mas, I. Pacchiarotti, Tábatha Maria Fernández, A. Bastidas, I. Agasi, M. Garriga, N. Verdolini, N. Arbelo, D. Nicolás, M. Valentí, A. Murru, Eduard Vieta, A. Solanes, F. Corponi, Bryan M. Li, D. Hidalgo-Mazzei
Eva María Sánchez‐Morla, Ana López-Villarreal, Estela Jiménez‐López, Ana Isabel Aparicio, Vicente Martínez‐Vizcaíno, Rodriguez-Jimenez Roberto, Eduard Vieta, José-Luis Santos
Anna Giménez‐Palomo, Mariona Guitart‐Mampel, Ana Meseguer, Roger Borràs, Francesc Josep García‐García, Esther Tobías, Laura Valls‐Roca, Xavier Alsina‐Restoy, Gemma Roqué, Ester Sànchez‐Tilló, Josep Roca, Gerard Anmella, Marc Valentí, L. Bracco, Helena Andreu, S. Salmerón, Lluc Colomer, Joaquim Raduà, Norma Verdolini, Michael Berk, Eduard Vieta, Glòria Garrabou,
Discussion(0)
No comments yet. Be the first to comment.